Previous 10 | Next 10 |
Akcea Therapeutics, Inc. (AKCA) Q2 2019 Earnings Conference Call Aug 6, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Jeff Goldeb...
Akcea Therapeutics (NASDAQ: AKCA ) Q2 results : More news on: Akcea Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Akcea Therapeutics (NASDAQ: AKCA ): Q2 GAAP EPS of -$0.40 beats by $0.05 . More news on: Akcea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Achieved Second Quarter 2019 TEGSEDI ® (inotersen) Global Net Product Revenues of $10 Million Conference Call Webcast Tuesday, August 6, 4:30 p.m. ET at www.akceatx.com BOSTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA),...
BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today topline results from the BROADEN study in patients with familial partia...
BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 6 th at 4:30 p.m. Eastern Time to discuss its second quarter 2019 financial results and report ...
BOSTON and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ambry Genetics Corporation (“Ambry”), a Konica Minolta company, announced an expansion of their collaboration as the t...
BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the NEURO-TTR open-label extension study and the clinical impac...
Results from a global open-label extension study evaluating the long-term effects of Alnylam Pharmaceuticals' ( ALNY -2.4% ) ONPATTRO (patisiran) in polyneuropathy of hereditary ATTR (hATTR) amyloidosis showed a sustained treatment benefit. The data were presented at the Peripheral Nerv...
BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the NEURO-TTR open-label extension study and the clinical impac...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...